Kolexia
Hasbini Ali Radio-thérapie
Hasbini Ali
Radio-thérapie
Polyclinique De Keraudren
Brest, France
127 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Carcinomes Adénocarcinome Néphrocarcinome Tumeurs de la tête et du cou Métastase tumorale Xérostomie Récidive tumorale locale

Collaborateurs

Voir plus
Latorzeff Igor
Latorzeff Igor
Hôpital Rangueil, Toulouse, France
Supiot Stephane
Supiot Stephane
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Laguerre Brigitte
Laguerre Brigitte
Centre Eugène Marquis, Rennes, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
A+A
118 collaboration(s)
Dernière en 2023
B3TSI
29 collaboration(s)
Dernière en 2023
Janssen
19 collaboration(s)
Dernière en 2023
Ipsen
19 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   03 février 2024
Bladder-ART: Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer: A Randomized Multicentre Phase II Study
Essai Clinique (Unicancer)   09 novembre 2023
PEACE1: A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Essai Clinique (Ipsen)   07 novembre 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
Survey by SFRO, SNRO and AFPPE about the evolution of the radiation therapist profession in France.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   25 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.
JAMA oncology   18 août 2023
Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   16 août 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
European urology   02 juin 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023